| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Kemeny N. Management of liver metastases from colorectal cancer[J]. Oncology (Williston Park), 2006, 20(10): 1161-1176, 1179.
|
| [3] |
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer[J]. Ann Surg, 2006, 244(2): 254-259.
|
| [4] |
Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival[J]. BMC Cancer, 2018, 18(1): 78.
|
| [5] |
Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy[J]. J Clin Oncol, 2009, 27(22): 3677-3683.
|
| [6] |
Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and Meta-analysis of prognostic factors[J]. Clin Epidemiol, 2012, 4: 283-301.
|
| [7] |
Inoue Y, Ishii M, Yokohama K, et al. Hepatectomy and liver regeneration in the results of treatment of colorectal liver metastasis[J]. Contemp Oncol (Pozn), 2020, 24(3): 172-176.
|
| [8] |
Akgül Ö, Çetinkaya E, Ersöz Ş, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122.
|
| [9] |
Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing[J]. Br J Cancer, 2007, 96(7): 1037-1042.
|
| [10] |
Malik HZ, Farid S, Al-Mukthar A, et al. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: A case-controlled study[J]. Ann Surg Oncol, 2007, 14(12): 3519-3526.
|
| [11] |
Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases[J]. Ann Surg Oncol, 2009, 16(1): 35-41.
|
| [12] |
Boostrom SY, Nagorney DM, Donohue JH, et al. Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases[J]. J Gastrointest Surg, 2009, 13(11): 2003-2009.
|
| [13] |
Scartozzi M, Siquini W, Galizia E, et al. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: better sooner than later? A retrospective analysis[J]. Dig Liver Dis, 2011, 43(3): 194-198.
|
| [14] |
Cucchetti A, Ercolani G, Cescon M, et al. Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy[J]. Langenbecks Arch Surg, 2012, 397(3): 397-405.
|
| [15] |
Pinto Marques H, Barroso E, de Jong MC, et al. Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?[J]. J Surg Oncol, 2012, 105(6): 511-519.
|
| [16] |
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1208-1215.
|
| [17] |
Scilletta R, Pagano D, Spada M, et al. Comparative analysis of the incidence of surgical site infections in patients with liver resection for colorectal hepatic metastases after neoadjuvant chemotherapy[J]. J Surg Res, 2014, 188(1): 183-189.
|
| [18] |
Bonney GK, Coldham C, Adam R, et al. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey[J]. J Surg Oncol, 2015, 111(6): 716-724.
|
| [19] |
Wiseman JT, Guzman-Pruneda F, Xourafas D, et al. Impact of neoadjuvant chemotherapy on the postoperative outcomes of patients undergoing liver resection for colorectal liver metastases: A population-based propensity-matched analysis[J]. J Am Coll Surg, 2019, 229(1): 69-77. e2.
|
| [20] |
Ratti F, Fuks D, Cipriani F, et al. Timing of perioperative chemotherapy does not influence long-term outcome of patients undergoing combined laparoscopic colorectal and liver resection in selected upfront resectable synchronous liver metastases[J]. World J Surg, 2019, 43(12): 3110-3119.
|
| [21] |
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
|
| [22] |
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group[J]. N Engl J Med, 2000, 343(13): 905-914.
|
| [23] |
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
|
| [24] |
Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy[J]. Ann Surg, 2008, 247(1): 118-124.
|
| [25] |
Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases[J]. J Am Coll Surg, 2005, 200(6): 845-853.
|
| [26] |
Liu W, Zhou JG, Sun Y, et al. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: A systematic review and Meta-analysis[J]. Oncotarget, 2016, 7(24): 37277-37287.
|
| [27] |
Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases[J]. Ann Surg Oncol, 2010, 17(11): 2870-2876.
|
| [28] |
Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases[J]. Surgery, 2009, 145(4): 362-371.
|
| [29] |
Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases[J]. Lancet, 2008, 371(9617): 963-965.
|
| [30] |
Macedo FI, Makarawo T. Colorectal hepatic metastasis: evolving therapies[J]. World J Hepatol, 2014, 6(7): 453-463.
|
| [31] |
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases[J]. Ann Surg, 1999, 230(3): 309-318; discussion 318-321.
|
| [32] |
Nagashima I, Takada T, Adachi M, et al. Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors[J]. World J Gastroenterol, 2006, 12(39): 6305-6309.
|
| [33] |
Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents[J]. J Am Coll Surg, 2007, 204(5): 753-763.
|
| [34] |
Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range[J]. Stat Methods Med Res, 2018, 27(6): 1785-1805.
|
| [35] |
Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range[J]. BMC Med Res Methodol, 2014, 14: 135.
|